Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-VV400 with or without rapamycin in relapsed/refractory large B-cell lymphoma
NCT06743503Phase 1Recruiting
- Sponsor
- Reindeer Biotech
- Start
- Apr 2025
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UB-VV400/410 in diffuse large B-cell lymphoma (DLBCL), sponsored by Reindeer Biotech. Primary endpoints: Adverse Events at 24 months and Maximum Tolerated Dose or Maximum Administered Dose at 24 months. Started Apr 2025; status: recruiting.
02
Drugs
UB-VV400/410
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06743503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06743503.